Narumi Nakagiri Analyst Performance

Narumi Nakagiri is a stock analyst at Daiwa Capital Markets in the medical sector, covering 2 publicly traded companies. Over the past year, Narumi Nakagiri has issued 2 stock ratings, including and hold recommendations. While full access to Narumi Nakagiri's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Narumi Nakagiri's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

2 Last 0 Years

Buy Recommendations

0.00% 0 Buy Ratings

Companies Covered

2 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	0.0%	0 ratings
Hold	100.0%	2 ratings
Sell	0.0%	0 ratings

the majority (100.0%) have been Hold recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NYSE	100.0% of companies on NYSE	2 companies

Narumi Nakagiri, an analyst at Daiwa Capital Markets, currently covers 2 companies listed on , with the majority traded on NYSE.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 2 companies	100.0%

Narumi Nakagiri of Daiwa Capital Markets specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
LARGE CAP PHARMA 1 company	50.0%
MED - BIOMED/GENE 1 company	50.0%

Narumi Nakagiri's Ratings History at Daiwa Capital Markets

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
LLY Eli Lilly and Company	8/17/2025	Downgrade	$701.51	$700.00	Neutral	$0.00 00.00% ROI
BMY Bristol Myers Squibb	8/5/2025	Downgrade	$45.39	$42.00	Neutral	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.